Stoneridge Investment Partners LLC lowered its position in Inovio Pharmaceuticals, Inc. (NASDAQ:INO) by 60.9% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 99,613 shares of the biopharmaceutical company’s stock after selling 154,836 shares during the period. Stoneridge Investment Partners LLC’s holdings in Inovio Pharmaceuticals were worth $781,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Candriam Luxembourg S.C.A. acquired a new stake in shares of Inovio Pharmaceuticals during the second quarter worth about $1,411,000. Private Capital Advisors Inc. acquired a new stake in shares of Inovio Pharmaceuticals during the second quarter worth about $274,000. Credit Suisse AG raised its stake in shares of Inovio Pharmaceuticals by 108.6% in the first quarter. Credit Suisse AG now owns 132,688 shares of the biopharmaceutical company’s stock worth $879,000 after buying an additional 69,068 shares in the last quarter. Metropolitan Life Insurance Co. NY raised its stake in shares of Inovio Pharmaceuticals by 8.5% in the first quarter. Metropolitan Life Insurance Co. NY now owns 51,573 shares of the biopharmaceutical company’s stock worth $341,000 after buying an additional 4,020 shares in the last quarter. Finally, Bank of America Corp DE raised its stake in shares of Inovio Pharmaceuticals by 14.6% in the first quarter. Bank of America Corp DE now owns 28,256 shares of the biopharmaceutical company’s stock worth $188,000 after buying an additional 3,605 shares in the last quarter. 22.92% of the stock is owned by hedge funds and other institutional investors.

Shares of Inovio Pharmaceuticals, Inc. (NASDAQ INO) opened at 5.49 on Friday. Inovio Pharmaceuticals, Inc. has a 12 month low of $5.32 and a 12 month high of $9.86. The firm’s 50-day moving average price is $6.88 and its 200-day moving average price is $6.81. The company’s market capitalization is $414.00 million.

Inovio Pharmaceuticals (NASDAQ:INO) last released its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.08. Inovio Pharmaceuticals had a negative return on equity of 63.67% and a negative net margin of 153.46%. The company had revenue of $20.41 million for the quarter, compared to analysts’ expectations of $16.29 million. During the same period in the prior year, the firm earned ($0.26) earnings per share. The firm’s revenue was up 229.2% compared to the same quarter last year. Equities research analysts expect that Inovio Pharmaceuticals, Inc. will post ($0.93) EPS for the current year.

WARNING: “Inovio Pharmaceuticals, Inc. (INO) Shares Sold by Stoneridge Investment Partners LLC” was posted by Daily Political and is the sole property of of Daily Political. If you are accessing this piece on another domain, it was illegally copied and reposted in violation of U.S. & international copyright legislation. The legal version of this piece can be viewed at https://www.dailypolitical.com/2017/08/11/inovio-pharmaceuticals-inc-ino-shares-sold-by-stoneridge-investment-partners-llc.html.

A number of brokerages recently issued reports on INO. ValuEngine raised Inovio Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Friday. HC Wainwright set a $13.00 price target on Inovio Pharmaceuticals and gave the stock a “buy” rating in a research note on Wednesday. Maxim Group set a $12.00 price target on Inovio Pharmaceuticals and gave the stock a “buy” rating in a research note on Wednesday. BidaskClub lowered Inovio Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, July 28th. Finally, Aegis reissued a “buy” rating and set a $14.00 price target on shares of Inovio Pharmaceuticals in a research note on Tuesday, July 18th. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and eight have given a buy rating to the company’s stock. Inovio Pharmaceuticals presently has a consensus rating of “Buy” and an average price target of $20.78.

In other Inovio Pharmaceuticals news, Director David B. Weiner sold 8,000 shares of the company’s stock in a transaction on Thursday, May 25th. The stock was sold at an average price of $8.00, for a total transaction of $64,000.00. Following the transaction, the director now directly owns 740,956 shares in the company, valued at $5,927,648. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 10.60% of the stock is owned by corporate insiders.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.

Want to see what other hedge funds are holding INO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Inovio Pharmaceuticals, Inc. (NASDAQ:INO).

Institutional Ownership by Quarter for Inovio Pharmaceuticals (NASDAQ:INO)

Receive News & Ratings for Inovio Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.